Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™

Leveraging emerging evidence presented at AAN, Dr. Angela Hirbe provides synthesis of key findings, highlight their relevance across pediatric and adult care, and frame practical considerations for patient assessment and longitudinal management.Launch/Release Date: April 24, 2026Activity Expiration Date: March 31, 2027FACULTYAngela Hirbe, MD, PhDAssociate Professor of Medicine and Pediatrics Director, Adult Neurofibromatosis Clinical Program Division of Oncology, Sarcoma Section Washington University School of Medicine St. Louis, MissouriThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Clinical care for myasthenia gravis is entering a period of meaningful progress, with growing opportunities to improve how the disease is diagnosed, assessed, and treated. Increased awareness of disease heterogeneity and the expanding use of standardized severity assessments are helping clinicians better define disease burden and guide management decisions.In this 20-minute podcast episode, Dr. James Howard Jr. provides comprehensive coverage of key MG presentations, scientific symposia, posters, and abstracts presented at AAN 2026.Launch/Release Date: April 23, 2026Activity Expiration Date: March 31, 2027FACULTYJames F. Howard, Jr., MD, FAANProfessor of Neurology, Medicine & Allied HealthDirector, Myasthenia Gravis Clinical Trials and Translational Research ProgramThe University of North Carolina at Chapel HillThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This activity will provide a comprehensive overview of NF1-PN and will dive deeper into the nuances of treating and managing adult patients with inoperable symptomatic NF1-PN. Dr. Angela Hirbe will use clinical cases to illustrate best-practice approaches to optimally identify adult patients with NF1-PN that will benefit from approved MEK inhibitors and will detail how to choose between agents and address/prevent adverse effects. The work-up and monitoring recommendations will also be discussed and any insights for achieving improved outcomes among diverse patients will be detailed. This presentation will empower participants to make informed clinical decisions for different patients with distinct needs.Launch/Release Date: October 16, 2025Activity Expiration Date: September 30, 2026FACULTYAngela Hirbe, MD, PhDAssociate Professor of Medicine and Pediatrics DirectorAdult Neurofibromatosis Clinical Program Division of Oncology Sarcoma SectionWashington University School of MedicineSt. Louis, MissouriThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

This activity will inform participants about the complex pathophysiology of NF1-PN and how an understanding of molecular pathways has led to the development of MEK inhibitors. The key published and ongoing clinical evidence on the utility of approved and emerging therapies for NF1-PN will be detailed to provide a strong foundation for clinical decision-making. An in-depth guide to recognize and diagnose patients with NF1-PN will also be discussed in this module to facilitate an accurate and timely diagnosis. Overall, this presentation will ensure that participants appreciate the need to recognize and treat NF1-PN among pediatric patients.Launch Date/Release Date: October 6, 2025Expiration Date: September 30, 2026FACULTYAmy Armstrong, MDAssistant Professor of PediatricsDivision of Hematology/OncologyNeurofibromatosis (NF) CenterWashington University School of MedicineSt. Louis, MissouriThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Gout remains the most common form of inflammatory arthritis in adults, yet it continues to be one of the most misunderstood and mismanaged chronic diseases in clinical practice. Despite clear treatment guidelines and a growing array of therapeutic options, a substantial proportion of patients experience persistent flares, disease progression, and comorbid complications due to clinical inertia, fragmented care, and limited provider awareness of emerging innovations. This podcast, presented by Dr. Robert Terkeltaub, seeks to modernize clinical approaches to gout, accelerate the adoption of new evidence and therapies, and ultimately improve the quality and consistency of care for a patient population long underserved by existing education.Launch Date/Release Date: September 23, 2025Expiration Date: August 31, 2026FACULTYRobert Terkeltaub, MDProfessor Emeritus of Medicine,University of California, San DiegoThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Stay informed on the go with our expert-led podcast series dedicated to stroke prevention. Across seven short episodes, Dr.'s C. Michael Gibson and Manesh Patel explore the shifting landscape of antithrombotic therapy—especially the potential role of Factor XIa inhibitors. From trial data to clinical applications, this series distills what you need to know to enhance patient care and reduce stroke risk.Launch Date: August 25, 2025Release Date: August 25, 2025Expiration Date: July 31, 2026FACULTYC. Michael Gibson, MD, MS, MA, FRCP, FAHA, FSCAI, FACCInterventional CardiologistBeth Israel LaheyCEOBaim Institute for Clinical ResearchProfessor of MedicineHarvard Medical School Manesh Patel, MDRichard Sean Stack, M.D. Distinguished ProfessorProfessor of MedicineChief, Division of CardiologyDuke University Health SystemThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

The introduction of kinase inhibitors has significantly impacted the treatment landscape of plexiform neurofibromas (PN) associated with neurofibromatosis type 1 (NF1). In this podcast activity from the 2025 Annual Oncology Meeting, noteworthy data in NF1-PN has been summarized and evaluated by Dr. Amy Armstrong. This activity is AMA/ABS/ANCC/ACPE accredited for one-year.Launch Date: June 5, 2025Release Date: June 5, 2025Expiration Date: May 31, 2026FACULTYAmy Armstrong, MDAssistant Professor of PediatricsDivision of Hematology/OncologyNeurofibromatosis (NF) CenterWashington University School of MedicineSt. Louis, MissouriThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from Day 2 of EASL 2025 and describe their implications for clinical practice.Launch Date: May 13, 2025Release Date: May 13, 2025Expiration Date: April 30, 2026FACULTYNancy Reau, MDSection Chief Professor of MedicineRichard B. Capps MD, Professorship of HepatologyRush University Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

There continues to be significant progress in the treatment of primary biliary cholangitis (PBC) and these Clinical Clips from EASL 2025 have focused on the most impactful data presented at this conference. Dr. Nancy Reau will summarize key advances from Day 1 of EASL 2025 and describe their implications for clinical practice.Launch Date: May 13, 2025Release Date: May 13, 2025Expiration Date: April 30, 2026FACULTYNancy Reau, MDSection Chief Professor of MedicineRichard B. Capps MD, Professorship of HepatologyRush University Medical CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

In this podcast titled "Emerging Evidence in Myasthenia Gravis: Key Updates from AAN 2025," Dr. Nicholas Silvestri provides healthcare professionals with an actionable update on recent advancements in MG; which features insights from groundbreaking research presented at AAN 2025.Launch Date: April 30, 2025Release Date: April 30, 2025Expiration Date: March 31, 2026FACULTYNicholas Silvestri, MD, FAANProfessor of Neurology, Associate Dean for Student and Academic AffairsDepartment of NeurologyJacobs School of Medicine & Biomedical SciencesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Join Dr. Nicholas Silvestri in this 8-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, The Future of MG Care: Innovations in Diagnostics and Guidelines, looks ahead at emerging technologies and the need for standardized international guidelines to harmonize MG management.Launch Date: April 28, 2025Release Date: April 28, 2025Expiration Date: March 31, 2026FACULTYNicholas Silvestri, MD, FAANProfessor of Neurology, Associate Dean for Student and Academic AffairsDepartment of NeurologyJacobs School of Medicine & Biomedical SciencesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Join Dr. Nicholas Silvestri in this 9-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Tailoring Treatment: The Role of Serotype Testing, discusses the impact of serotype testing on treatment decisions, including differences in therapeutic approaches for AChR-positive, MuSK-positive, and LRP4-positive patients.Launch Date: April 24, 2025Release Date: April 24, 2025Expiration Date: March 31, 2026FACULTYNicholas Silvestri, MD, FAANProfessor of Neurology, Associate Dean for Student and Academic AffairsDepartment of NeurologyJacobs School of Medicine & Biomedical SciencesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Join Dr. Nicholas Silvestri in this 10-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Innovations in MG Therapeutics, focuses on the latest therapies, including complement inhibitors and FcRn antagonists, and their application in personalized treatment plans.Launch Date: April 21, 2025Release Date: April 21, 2025Expiration Date: March 31, 2026FACULTYNicholas Silvestri, MD, FAANProfessor of Neurology, Associate Dean for Student and Academic AffairsDepartment of NeurologyJacobs School of Medicine & Biomedical SciencesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Join Dr. Nicholas Silvestri in this 8-minute, special edition podcast series on myasthenia gravis (MG). Today’s podcast titled, Advancements in Myasthenia Gravis Diagnosis, highlights the limitations of traditional diagnostic methods and introduces emerging technologies such as high-sensitivity serotype testing and advanced neurophysiological techniques.Launch Date: April 17, 2025Release Date: April 17, 2025Expiration Date: March 31, 2026FACULTYNicholas Silvestri, MD, FAANProfessor of Neurology, Associate Dean for Student and Academic AffairsDepartment of NeurologyJacobs School of Medicine & Biomedical SciencesThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Please refer to the activity landing page for the downloadable slides.Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease that can progress to end-stage liver disease. Recent developments have led to important updates in the diagnosis and use of novel approaches in treatment for patients with PBC. This podcast will utilize case-based discussion to address implications of risk stratification and practice-changing evidence for the long-term management among diverse patients with PBC.Launch Date: January 21, 2025Release Date: January 21, 2025Expiration Date: December 31, 2025FACULTYDavid W. Victor III, MDAssociate Professor of Clinical MedicineHouston Methodist Research InstituteThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided in this link prior to listening to this podcast.

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish HospitalDirector Clinical Trials, University of LouisvilleThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/clinical-clips174-from-aasld-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis-17

This podcast features an engaging discussion between Dr. Douglas Dieterich and his patient with long-standing PBC, on the patient’s insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: November 21, 2024Release Date: November 21, 2024Expiration Date: October 31, 2025FACULTYDouglas Dieterich, MDDirector, Institute for Liver Medicine at Mount SinaiProfessor of Medicine, Icahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

This podcast features an engaging discussion between Dr. David Victor and his patient, with long-standing PBC, on the patient’s insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: October 24, 2024Release Date: October 24, 2024Expiration Date: September 30, 2025FACULTYDavid W. Victor III, MDAssociate Professor of Clinical MedicineHouston Methodist Research InstituteAssociate Professor of Clinical MedicineWeill Cornell MedicineThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

This podcast features an engaging discussion between Dr. Douglas Dieterich and his patient, a 54-year-old woman with long-standing PBC, on the patient’s insights and experiences with her disease and treatment. The activity will enable participants to understand the importance of listening to patient perspectives when designing individualized care pathways to alleviate symptoms and improve quality of life.Launch Date: August 21, 2024Release Date: August 21, 2024Expiration Date: July 31, 2025FACULTYDouglas Dieterich, MDDirector, Institute for Liver Medicine at Mount SinaiProfessor of Medicine, Icahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/patient-voices-in-primary-biliary-cholangitis-a-ce-podcast-series-to-recognize-challenges-reduce-disparities-and-improve-outcomes

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit.Launch Date: June 11, 2024Release Date: June 11, 2024Expiration Date: May 31, 2025Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis

Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies will be presented at the annual European Association for the Study of the Liver (EASL) 2024 Congress in Milan, Italy. In this podcast series, Dr. Kris Kowdley will discuss the most important breakthroughs in the understanding and treatment of PBC presented at the EASL Congress 2024 and will provide guidance on their impact.This is an accredited continuing education podcast as downloadable audio file (MP3) available for AMA/ABS/ANCC/ACPE credit.Launch Date: June 11, 2024Release Date: June 11, 2024Expiration Date: May 31, 2025Faculty BioKris V. Kowdley, MD, AGAF, FAASLD, FACG, FACPDirector, Liver Institute NorthwestProfessor, Elson S. Floyd College of MedicineWashington State UniversityThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link below prior to listening to this podcast.https://www.practicepointcme.com/CMEHome/podcast-from-easl-congress-2024-key-breakthroughs-in-the-treatment-of-primary-biliary-cholangitis